دورية أكاديمية
TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus.
| العنوان: | TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus. |
|---|---|
| المؤلفون: | Diehl DL; Department of Gastroenterology, Geisinger Health System, Danville, Pennsylvania, United States., Khara HS; Department of Gastroenterology, Geisinger Health System, Danville, Pennsylvania, United States., Akhtar N; Department of Gastroenterology, Geisinger Health System, Danville, Pennsylvania, United States., Critchley-Thorne RJ; Cernostics, Inc., Pittsburgh, Pennsylvania, United States. |
| المصدر: | Endoscopy international open [Endosc Int Open] 2021 Mar; Vol. 9 (3), pp. E348-E355. Date of Electronic Publication: 2021 Feb 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Georg Thieme Verlag KG Country of Publication: Germany NLM ID: 101639919 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2364-3722 (Print) Linking ISSN: 21969736 NLM ISO Abbreviation: Endosc Int Open Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Stuttgart : Georg Thieme Verlag KG, [2013]- |
| مستخلص: | Background and study aims The TissueCypher Barrett's Esophagus Assay is a novel tissue biomarker test, and has been validated to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE). The aim of this study was to evaluate the impact of TissueCypher on clinical decision-making in the management of BE. Patients and methods TissueCypher was ordered for 60 patients with non-dysplastic (ND, n = 18) BE, indefinite for dysplasia (IND, n = 25), and low-grade dysplasia (LGD, n = 17). TissueCypher reports a risk class (low, intermediate or high) for progression to HGD or EAC within 5 years. The impact of the test results on BE management decisions was assessed. Results Fifty-two of 60 patients were male, mean age 65.2 ± 11.8, and 43 of 60 had long segment BE. TissueCypher results impacted 55.0 % of management decisions. In 21.7 % of patients, the test upstaged the management approach, resulting in endoscopic eradication therapy (EET) or shorter surveillance interval. The test downstaged the management approach in 33.4 % of patients, leading to surveillance rather than EET. In the subset of patients whose management plan was changed, upstaging was associated with a high-risk TissueCypher result, and downstaging was associated with a low-risk result ( P < 0.0001). Conclusions TissueCypher was used as an adjunct to support a surveillance-only approach in 33.4 % of patients. Upstaging occurred in 21.7 % of patients, leading to therapeutic intervention or increased surveillance. These results indicate that the TissueCypher test may enable physicians to target EET for TissueCypher high-risk BE patients, while reducing unnecessary procedures in TissueCypher low-risk patients. Competing Interests: Competing interests Dr. Diehl is a consultant for Cernostics and has ownership interest (stock options) in Cernostics, Inc. Dr. Critchley-Thorne has ownership interest (stock, stock options and patents) in Cernostics, Inc. (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).) |
| References: | Gastroenterology. 2005 Aug;129(2):429-36. (PMID: 16083700) Gut. 2012 Jul;61(7):970-6. (PMID: 21997553) Gastrointest Endosc. 2020 Jan;91(1):3-10.e3. (PMID: 31421077) Methods Mol Biol. 2018;1711:261-273. (PMID: 29344894) Dig Dis Sci. 2018 Aug;63(8):1988-1996. (PMID: 29671158) Clin Gastroenterol Hepatol. 2011 Mar;9(3):220-7; quiz e26. (PMID: 21115133) Clin Gastroenterol Hepatol. 2019 Apr;17(5):832-834. (PMID: 30267865) J Pathol Inform. 2015 Aug 31;6:48. (PMID: 26430536) Curr Med Res Opin. 2017 Jun;33(6):1091-1097. (PMID: 28277859) Arch Pathol Lab Med. 2010 Oct;134(10):1479-84. (PMID: 20923304) Breast Cancer Res Treat. 2013 Aug;141(1):13-22. (PMID: 23974828) Am J Gastroenterol. 2020 Jun;115(6):843-852. (PMID: 32079863) Adv Ther. 2016 Apr;33(4):684-97. (PMID: 26942725) Sci Rep. 2020 Mar 17;10(1):4899. (PMID: 32184470) Hum Pathol. 2001 Apr;32(4):368-78. (PMID: 11331953) Gastrointest Endosc. 2018 Nov;88(5):807-815.e2. (PMID: 29944863) Gastroenterology. 2017 Feb;152(3):564-570.e4. (PMID: 27818167) Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. (PMID: 31439127) Gastroenterology. 2011 Mar;140(3):1084-91. (PMID: 21376940) Clin Gastroenterol Hepatol. 2016 Aug;14(8):1086-1095.e6. (PMID: 27068041) Clin Gastroenterol Hepatol. 2018 Jul;16(7):1046-1055.e8. (PMID: 29199147) Am J Gastroenterol. 2021 Apr;116(4):675-682. (PMID: 33982936) Clin Transl Gastroenterol. 2020 Oct;11(10):e00244. (PMID: 33108124) Am J Gastroenterol. 2019 Aug;114(8):1256-1264. (PMID: 30865017) Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51. (PMID: 26526079) Clinicoecon Outcomes Res. 2019 Oct 25;11:623-635. (PMID: 31749626) Clin Gastroenterol Hepatol. 2013 Nov;11(11):1430-6. (PMID: 23707463) Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310) Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):958-68. (PMID: 27197290) Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):240-248. (PMID: 27729357) |
| تواريخ الأحداث: | Date Created: 20210303 Latest Revision: 20210609 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7892269 |
| DOI: | 10.1055/a-1326-1533 |
| PMID: | 33655033 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2364-3722 |
|---|---|
| DOI: | 10.1055/a-1326-1533 |